Isaac Witz

Q: What Schools Are Affiliated With Isaac Witz

Isaac Witz is affiliated with the following schools: Weizmann Institute of Science, Hebrew University of Jerusalem, Tel Aviv University, University System of Maryland

Isaac Witz's AcademicInfluence.com Rankings

Isaac Witz

Biology

#4674

World Rank

#6952

Historical Rank

Biochemistry

#1420

World Rank

#1544

Historical Rank

Molecular Biology

#2425

World Rank

#2463

Historical Rank

biology Degrees

Download Badge

Biology

Isaac Witz's Degrees

Bachelors Biochemistry Tel Aviv University
Masters Biochemistry Tel Aviv University
PhD Biochemistry Weizmann Institute of Science

Why Is Isaac Witz Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Isaac P. Witz is an Israeli Immunologist and cancer researcher, professor Emeritus at the Shmunis School of Biomedicine and Cancer Research in Tel Aviv University . The former vice president for Research and Development and the Dean of Faculty of Life Sciences. A world-renowned cancer researcher and one of the scientists who laid the foundations of the Tumor Microenvironment research field.

(See a Problem?)

Isaac Witz's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A Possible Role for CXCR4 and Its Ligand, the CXC Chemokine Stromal Cell-Derived Factor-1, in the Development of Bone Marrow Metastases in Neuroblastoma1 (2001) (415)
A history of exploring cancer in context (2018) (280)
CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. (2007) (180)
The selectin–selectin ligand axis in tumor progression (2008) (137)
The Tumor Microenvironment: The Making of a Paradigm (2009) (135)
The tumor microenvironment in the post-PAGET era. (2006) (128)
Tumor-microenvironment interactions: dangerous liaisons. (2008) (123)
The CASC15 long intergenic non-coding RNA locus is involved in melanoma progression and phenotype-switching (2015) (96)
Yin-yang activities and vicious cycles in the tumor microenvironment. (2008) (95)
The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. (2004) (93)
Tumor-bound immunoglobulins: in situ expressions of humoral immunity. (1977) (88)
The focal adhesion kinase (P125FAK) is constitutively active in human malignant melanoma (2002) (82)
Tumor-Microenvironment Interactions (2004) (81)
Astrocytes facilitate melanoma brain metastasis via secretion of IL‐23 (2015) (77)
PROTECTIVE AND CELLULAR IMMUNE RESPONSES TO IDIOTYPIC DETERMINANTS ON CELLS FROM A SPONTANEOUS LYMPHOMA OF NZB/NZW F1 MICE (1974) (75)
Epigenetic Changes of EGFR play an important role in BRAF inhibitor Resistant Cutaneous Melanomas (2014) (75)
The relationship between in vitro fertilization and naturally occurring antibodies: evidence for increased production of antiphospholipid autoantibodies. (1991) (74)
The metastatic microenvironment: Brain‐residing melanoma metastasis and dormant micrometastasis (2012) (72)
Progression of mouse mammary tumors: MCP‐1‐TNFα cross‐regulatory pathway and clonal expression of promalignancy and antimalignancy factors (2003) (69)
Tumor‐associated immunoglobulins. enhancement of syngeneic tumors by igg2‐containing tumor eluates (1972) (67)
Hexokinase 2 is a determinant of neuroblastoma metastasis (2016) (64)
Chemokine-chemokine receptor axes in melanoma brain metastasis. (2010) (62)
Tissue-binding factor in schizophrenic sera: a clinical and genetic study. (1977) (54)
CCR4 is a determinant of melanoma brain metastasis (2017) (52)
Tumor‐bound immunoglobulins. Evidence for the in vivo coating of tumor cells by potentially cytotoxic anti‐tumor antibodies (1976) (52)
The role played by the microenvironment in site-specific metastasis. (2014) (51)
The biological significance of tumor-bound immunoglobulins. (1973) (49)
Tumor‐associated immunogolobulins. The elution of IgG2 from mouse tumors (1970) (46)
The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells. (2009) (45)
Circulating cellfree Fc gamma 2b/gamma 1 receptor in normal mouse serum: its detection and specificity. (1984) (45)
Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells. (2015) (45)
The involvement of selectins and their ligands in tumor-progression. (2006) (44)
Cancer drug resistance induced by EMT: novel therapeutic strategies (2021) (42)
Human Ly‐6 antigen E48 (Ly‐6D) regulates important interaction parameters between endothelial cells and head‐and‐neck squamous carcinoma cells (2002) (39)
MCP-1 expression as a potential contributor to the high malignancy phenotype of murine mammary adenocarcinoma cells. (1999) (39)
Cellular characteristics of neuroblastoma cells: regulation by the ELR--CXC chemokine CXCL10 and expression of a CXCR3-like receptor. (2005) (38)
The metastatic microenvironment: Claudin‐1 suppresses the malignant phenotype of melanoma brain metastasis (2015) (37)
Dual-specificity phosphatase Pyst2-L is constitutively highly expressed in myeloid leukemia and other malignant cells (2003) (35)
E‐selectin regulates gene expression in metastatic colorectal carcinoma cells and enhances HMGB1 release (2008) (35)
AN association between high Ly‐6A/E expression on tumor cells and a highly malignant phenotype (1994) (34)
Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia. (2003) (33)
The GPI-linked Ly-6 Antigen E48 Regulates Expression Levels of the FX Enzyme and of E-selectin Ligands on Head and Neck Squamous Carcinoma Cells* (2000) (32)
Increased Antiphospholipid Antibody Activity in In‐Vitro Fertilization Patients Is Not Treatment‐Dependent but Rather an Inherent Characteristic of the Infertile State (1995) (32)
Differential tumorigenicity of 3T3 cells transformed in vitro with polyoma virus and in vivo selection for high tumorigenicity. (1989) (32)
Tumor-microenvironment interactions: the selectin-selectin ligand axis in tumor-endothelium cross talk. (2006) (32)
The murine Fc‐gamma (Fcγ) receptor type II B1 is a tumorigenicity‐enhancing factor in polyoma‐virus‐transformed 3T3 cells (1996) (31)
Serologically detectable MHC and tumor-associated antigens on B16 melanoma variants and humoral immunity in mice bearing these tumors. (1982) (31)
Natural host defence during oncogenesis. NK activity and dimethylbenzanthracene carcinogenesis (1983) (31)
The tumor microenvironment: CXCR4 is associated with distinct protein expression patterns in neuroblastoma cells. (2004) (30)
Receptors for immune complexes on cells within a non-lymphoid murine tumor. (1976) (30)
The metastatic microenvironment: Brain‐derived soluble factors alter the malignant phenotype of cutaneous and brain‐metastasizing melanoma cells (2012) (30)
The metastatic microenvironment: Melanoma–microglia cross‐talk promotes the malignant phenotype of melanoma cells (2018) (29)
Differential expression of genes by tumor cells of a low or a high malignancy phenotype: The case of murine and human Ly‐6 proteins (2000) (29)
In vivo acquisition of Fc gamma RII expression on polyoma virus-transformed cells derived from tumors of long latency. (1991) (28)
cDNA microarray analysis reveals an overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia. (2003) (28)
Tumour-bound immunoglobulins. The in vitro fixation of radioiodine-labelled anti-immunoglobulin reagents by tumour cells. (1974) (27)
The Beta Subunit of Hemoglobin (HBB2/HBB) Suppresses Neuroblastoma Growth and Metastasis. (2017) (26)
Generation and characterization of novel local and metastatic human neuroblastoma variants. (2008) (26)
Serologically detectable specific and cross‐reactive antigens on the membrane of a polyoma virus‐induced murine tumor (1976) (26)
IgG associated with microsomes from autochthonous hepatomas and normal liver of rats. (1967) (25)
Receptors for immune complexes on cells within a polyoma virus‐induced murine sarcoma (1976) (23)
Differences in cell density associated with differences in lung-colonizing ability of B16 melanoma cells. (1981) (23)
Tumour-bound immunoglobulins. The fate of immunoglobulin disappearing from the surface of coated tumour cells. (1974) (23)
Possible co-regulation of genes associated with enhanced progression of mammary adenocarcinomas. (2002) (22)
Contribution of the intracellular domain of murine FC‐gamma receptor type IIB1 to its tumor‐enhancing potential (1996) (22)
Tumor bound immunoglobulins: The relationship between the in vivo coating of tumor cells by potentially cytotoxic anti‐tumor antibodies, and the expression of immune complex receptors (1976) (22)
Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis (2020) (21)
Increased expression of Fc gamma receptor in cancer patients and tumor bearing mice. (1988) (20)
The involvement of the sLe-a selectin ligand in the extravasation of human colorectal carcinoma cells. (2008) (20)
Generation of non-complement-fixing, blocking factors by lysosomal extract treatment of cytotoxic anti-tumor antibodies. (1974) (20)
The effect of lithium chloride on tumour appearance and survival of melanoma-bearing mice. (1983) (20)
The participation of trimethylammonium in the mouse erythrocyte epitope recognized by monoclonal autoantibodies. (1981) (20)
The Metastatic Microenvironment (2013) (19)
The metastatic microenvironment: Lung‐derived factors control the viability of neuroblastoma lung metastasis (2013) (19)
Tumour-bound immunoglobulins. The in vitro disappearance of immunoglobulin from the surface of coated tumour cells, and some properties of released components. (1974) (19)
A review of data, problems, and open questions pertaining to in situ tumor immunity. (1980) (18)
FcR may function as a progression factor of nonlymphoid tumors (1992) (18)
Lung-residing metastatic and dormant neuroblastoma cells. (2011) (18)
Gene‐expression‐based analysis of local and metastatic neuroblastoma variants reveals a set of genes associated with tumor progression in neuroblastoma patients (2009) (18)
Characterization of immunoglobulins eluted from murine tumor cells: binding patterns of cytotoxic anti-tumor IgG. (1978) (18)
The FX enzyme is a functional component of lymphocyte activation. (2001) (17)
Studies on the level of natural antibodies reactive with various tumor cells during urethane carcinogenesis in BALB/c mice. (1984) (17)
Degradation of immunoglobulins by lysosomal enzymes of tumors. I. Demonstration of the phenomenon using mouse tumors. (1973) (16)
Tumor‐bound immunoglobulins. I. Further analysis of the characteristics of binding of immunoglobulins to In vivo‐grown tumor cells (1976) (15)
Regeneration Enhances Metastasis: A Novel Role for Neurovascular Signaling in Promoting Melanoma Brain Metastasis (2019) (15)
Serological detection of a polyoma‐tumor‐associated membrane antigen (1979) (15)
Receptors involved in microenvironment-driven molecular evolution of cancer cells. (2002) (15)
The elution of antibodies from viable murine tumor cells. (1979) (14)
Characterization of the dual‐specificity phosphatase PYST2 and its transcripts (2004) (14)
ANGPTL4 promotes the progression of cutaneous melanoma to brain metastasis. (2017) (14)
Site‐specific metastasis: A cooperation between cancer cells and the metastatic microenvironment (2020) (14)
The immune system during the precancer period: naturally-occurring tumor reactive monoclonal antibodies and urethane carcinogenesis. (1988) (14)
Epigenomic landscape of melanoma progression to brain metastasis: unexplored therapeutic alternatives. (2015) (14)
In Situ Expression of Tumor Immunity (1980) (13)
Cystatin C takes part in melanoma-microglia cross-talk: possible implications for brain metastasis (2018) (13)
Relationship between choline derivatives and mouse erythrocyte membrane antigens revealed by mouse monoclonal antibodies. I. Anticholine activity of anti-mouse erythrocyte monoclonal antibodies. (1982) (13)
The tumour microenvironment--introduction. (2002) (13)
Does the dual-specificity MAPK phosphatase Pyst2-L lead a monogamous relationship with the Erk2 protein? (2004) (12)
CYTOTOXICITY AND CYTOSTASIS MEDIATED BY SPLENOCYTES OF MICE SUBJECTED TO CHEMICAL CARCINOGENS AND OF MICE-BEARING PRIMARY TUMORS (1980) (12)
Suppression of immune response to sheep red blood cells in mice treated with preparations of a tumor cell component and in tumor‐bearing mice (1975) (12)
P-REX1 amplification promotes progression of cutaneous melanoma via the PAK1/P38/MMP-2 pathway. (2017) (12)
Expression of Fcγ Receptors on a Subpopulation of Nonlymphoid Tumor Cells and Its Enrichment (1984) (12)
Lymphocytotoxic autoantibodies eluted from in vivo propagating sarcoma cells of mice. (1978) (12)
Phenotypic properties of 3T3 cells transformed in vitro with polyoma virus and passaged once in syngeneic animals. (1992) (12)
The specific blocking of humoral immune cytolysis mediated by anti‐tumor antibodies degraded by lysosomal enzymes of tumor origin (1975) (12)
CD5+ B cells and naturally occurring autoantibodies in cancer patients (1991) (11)
Do naturally occurring antibodies play a role in the progression and proliferation of tumor cells? (1988) (11)
Presence and functions of immune components in the tumor microenvironment. (2001) (11)
Some characteristics of natural cytostatic mouse splenocytes. (1981) (11)
ANGPTL4 promotes the progression of cutaneous melanoma to brain metastasis (2017) (11)
Moloney Lymphoma Antibodies from Mice; Localization in Spleens of Moloney Lymphoma Bearing Mice∗ (1969) (11)
Possibilities of interference with the immune system of tumor bearers by non-lymphoid Fc gamma RII expressing tumor cells. (1992) (11)
Tumor-localizing lymphocytotoxic antibodies. (1980) (10)
Purification and Partial Characterization of Mouse Hemopexin (Beta 2-III Globulin).∗ (1965) (10)
TNFalpha and anti-Fas antibodies regulate Ly-6E.1 expression by tumor cells: a possible link between angiogenesis and Ly-6E.1. (1996) (10)
Late immune and haemopoietic functions in plasmacytoma-bearing mice cured by melphalan. (1988) (10)
FcR derived from without the immune system--a potential escape mechanism for cells propagating in a hostile immunological environment. (1985) (10)
Increased ribonuclease activity in thymus and lymph nodes after intraperitoneal antigenic stimulation with sheep erythrocytes. (1971) (9)
Availability of isoantigens to circulating antibodies. (1968) (9)
The Antigenic Composition of Tumours, Sera and Urines of Tumour-Bearing Mice and the Partial Purification of Two Antigens Present in Increased Amounts (1964) (9)
The Challenge of Classifying Metastatic Cell Properties by Molecular Profiling Exemplified with Cutaneous Melanoma Cells and Their Cerebral Metastasis from Patient Derived Mouse Xenografts* (2019) (9)
Microenvironmental factors regulate Ly-6 A/E expression on PyV-transformed BALB/c 3T3 cells. (1995) (9)
Some immunological properties of high and low tumorigenic cellular variants of c-H-ras transformed 3T3 cells. (1988) (9)
Could Fc-receptors facilitate the escape of immunogenic premalignant cells from host deffence? a hypothesis (1985) (9)
Antibody‐dependent cell‐mediated cytotoxic activity in syngeneic mouse ascites tumors (1975) (9)
B16 melanoma development, NK activity cytostasis and natural antibodies in 3 and 12 month old mice. (1984) (8)
Autoantibody‐Mediated Regulation of Tumor Growth a (1992) (8)
Separation of tumor-seeking small lymphocytes and tumor cells using Percoll velocity gradients. (1981) (7)
A radioimmunoassay with monoclonal antibodies for the detection of antigenic cell-free Fc receptor. (1984) (7)
The 5th International Conference on Tumor Microenvironment: Progression, Therapy and Prevention Versailles, France, October 20–24, 2009 (2010) (7)
PHOX2B is a suppressor of neuroblastoma metastasis (2016) (7)
A normal component in ribbit IgG with affinity for mouse tissues. (1968) (7)
Inter-Tumor Heterogeneity—Melanomas Respond Differently to GM-CSF-Mediated Activation (2020) (7)
Tumor-associated immunoglobulins. (1971) (6)
Placenta-bound immunoglobulins. (1979) (6)
Incorporation of 125-I-iododeoxyuridine into target cells as an assay for cell immunity. (1974) (6)
Hybridomas from unimmunized individuals. (1986) (6)
Comparison of NK activity in mouse spleen and peripheral blood lymphocytes. (1988) (6)
Antigenic composition of normal tissues and tumors in an inbred strain of mice. (1961) (6)
The immunosuppressive capacity of alloantisera in mice, including sera directed primarily against thymic antigens. (1971) (6)
Correlation between clinico-pathological features of malignant tumors and cell surface immunoglobulins. (1974) (6)
Dynamic alterations in some surface properties of freshly explanted Moloney lymphoma cells. (1975) (5)
Tumor-bound immunoglobulins: their possible role in circumventing antitumor immunity. (1974) (5)
The melanoma brain metastatic microenvironment: aldolase C partakes in shaping the malignant phenotype of melanoma cells – a case of inter‐tumor heterogeneity (2020) (5)
From Molecular to Modular Tumor Therapy Tumors are Reconstructible Communicatively Evolving Systems (2013) (5)
Suppressed plaque and rosette-formation by spleen cells of mice injected with tumor extracts. (1973) (5)
Antigenic Composition of Normal Tissues and Tumours in an Inbred Strain of Mice. Changes in Certain Globulins Associated with Tumour Growth (1961) (4)
Immunological approaches to cancer therapeutics: edited by E. Mihich. John Wiley and Sons, New York, 1982 (x + 587 pp., illus., author and subject indices) (1983) (4)
Immunosuppressive activity of mouse alloantibodies. (1969) (4)
Natural killer cells and naturally occurring antibodies as representatives of natural tumor immunity. (1982) (4)
Unsung Hero Robert C. Gallo (2009) (4)
Marker and function analysis of natural killer and alloreactive T cells during early stages of dimethylbenzanthracene carcinogenesis. The immunity system during the precancer period. (1986) (4)
The Inflammatory Milieu of Tumors: Cytokines and Chemokines that Affect Tumor Growth and Metastasis (2018) (4)
C-110 The Metastatic Microenvironment: A New Lung-Derived Factor Inhibits Neuroblastoma Lung Metastasis (2014) (4)
The effect of short‐term culture on the sensitivity of MDAY murine tumor cells to lysis mediated by normal rabbit serum (1976) (4)
THE SUPPRESSION OF NK ACTIVITY BY THE CHEMICAL CARCINOGEN DIMETHYLBENZANTHRACENE AND ITS RESTORATION BY INTERFERON OR POLY I:C (1982) (4)
Binding patterns of immunoglobulins from tumor-bearing mice to the corresponding tumor cells. (1978) (4)
Detection of immunoglobulin A anticardiolipin antibodies in cervical mucus from in vitro fertilization patients and fertile women. (1995) (4)
Further studies on the determinant recognized by naturally-occurring murine autoantibodies reacting with bromelain-treated erythrocytes. (1988) (4)
Isoantigens available to circulating antibodies. (1969) (4)
Immunosuppressive Activity of Rabbit Antisera Directed against Mouse Lymphocytic Leukemia L1210∗ (1968) (4)
Some cellular and molecular characteristics of high and low tumorigenicity variants of polyoma-virus transformed cells. (1990) (4)
A human monoclonal IgA autoantibody—185/12—behaves like an autoimmune antiphospholipid antibody (1994) (3)
Degradation of cell-bound antibodies by tumor cells from C57BL/6 mice. (1978) (3)
Monoclonal antibodies from mice bearing polyoma virus-induced tumor (1982) (3)
The relationship of membrane antigens on 141 (NZB) and EL4 (C57BL) lymphoma cells as demonstrated by antibodyinduced resistance to complement‐mediated cytotoxicity (1978) (3)
Constitutive low expression of antiviral effectors sensitizes melanoma cells to a novel oncolytic virus (2020) (3)
Detection of hemopoietic allografts by localization of radiolabeled alloantibodies. (1970) (3)
Natural defense and chemical carcinogenesis. (1985) (3)
Availability of transplantation alloantigens to circulating antibodies: studies with alloantibodies of known specificity. (1969) (3)
In Situ Expressions of Humoral Immunity within a Polyoma-Virus-Induced Tumor (1979) (3)
The Challenge of Classifying Metastatic Cell Properties by Molecular Profiling Exemplified with Cutaneous Melanoma Cells and Their Cerebral Metastasis from Patient Derived Mouse Xenografts. (2020) (3)
Cancer microenvironment and genomics: evolution in process (2021) (3)
Brain Localizing Activity of Hetero- and Isoimmune Sera Directed against Lymphocytic Cells∗ (1969) (3)
Naturally-occurring tumor-reactive autoantibodies: a monoclonal antibody from normal mice reacts with tumor cells and with DNA. (1988) (3)
Lung colonization by and heparanase activity in in vitro transformed 3T3 cells rendered highly tumorigenic by an in vivo passage. (1994) (2)
A Tissue-Binding Factor in the Serum of Schizophrenic Patients (1977) (2)
Preleukemia in long-term plasmacytoma-regressor mice. (1998) (2)
Preleukemia in long‐term plasmacytoma‐regressor mice (1998) (2)
The ability of thymus and bone marrow cells from immunized donors to restore antibody formation to BSA in irradiated mice. (1972) (2)
Myeloproliferation in long‐term plasmacytoma‐regressor mice (1994) (2)
LY6S, a New IFN-Inducible Human Member of the Ly6a Subfamily Expressed by Spleen Cells and Associated with Inflammation and Viral Resistance (2021) (2)
FURTHER STUDIES ON THE CYTOSTATIC ACTIVITY MEDIATED BY MURINE SPLENOCYTES (1982) (2)
Natural cellular defense activities against tumors--cytostasis and NK activity. (1983) (2)
Immune Reactivities During the Precancer and Early Cancer Periods: Novel Approaches for Immunomodulation (1986) (2)
In vivo tumorigenicity and in vitro sensitivity to tumor-necrosis-factorα mediated killing of c-Ha-ras-transformed cells (2005) (1)
Cytokine network imbalances in plasmacytoma-regressor mice. (1999) (1)
Effect in vivo of recombinant GM‐CSF on neutropenia and survival in mice treated by high‐dose melphalan (1989) (1)
Introducing the Cancer Microenvironment Section of Journal of Translational Medicine (2010) (1)
Alkaline ribonuclease activity in lymphoid organs of mice after injection of tumor cells (1974) (1)
Development of a multivalent live vaccine active against a wide range of Enterobacteriaceae. (1980) (1)
The role of the tumor microenvironment in tumor progression (2007) (1)
"The involvement of Fc receptors in tumor progression". (1992) (1)
Chapter 2 The Metastatic Microenvironment (2017) (1)
The tumor microenvironment: the involvement of the selectin-selectin-ligand axis in tumor-endothelium interactions (2006) (1)
Bearing certain tumors may result in autoimmunity. (1988) (1)
The fate of IgM and of anti IgM on antibody-coated Daudi cells (1976) (1)
Expression of Fc gamma receptors on a subpopulation of nonlymphoid tumor cells and its enrichment. (1984) (1)
The cross talk between cancer cells and their microenvironments. (2022) (1)
Immunosuppressive activity of mouse alloantibodies. Abstr. (1969) (0)
The involvement of FcτRII and Ly-6/Sca-1 in the progression of mouse tumors (2007) (0)
In Vivo Acquisition of FcTRH Expression on Polyoma Virus-transformed Cells Derived from Tumors of Long Latency1 (2006) (0)
PURIFICATION AND PARTIAL CHARACTERIZATION OF MOUSE HEMOPEXIN (BETA 2-3 GLOBULIN). (1965) (0)
Cystatin C takes part in melanoma-microglia cross-talk: possible implications for brain metastasis (2018) (0)
The immune detection and quantitation of antigenic cell-free Fc receptor by solid phase RIA employing monoclonal anti FcR antibody. (1984) (0)
A 3T3-cell derived factor triggers the release of a self mitogen from Fcγ receptor expressing T cells (1987) (0)
In-vivo localization properties of antibodies directed against a mouse leukemia grown in cell culture. Abstr. (1968) (0)
The presence of cells expressing immune-complex receptors in non-lymphoid murine tumors. (1976) (0)
Commentarythe Cancer Microenvironment Section of Journal of Translational Medicine (2010) (0)
Idiotype-binding cells in plasmacytoma-bearing mice. (1979) (0)
Serologic studies on schizophrenic patients. (1978) (0)
192 Cross-Talk with the Microenvironment: The Case of Melanoma Brain Metastasis (2011) (0)
CHARACTERISTICS OF NATURAL CYTOSTATIC EFFECTOR CELLS (1980) (0)
Antibody-dependent cell-mediated cytotoxic activity in syngeneic moouse ascites tumors. (1975) (0)
Late Submissions (1984) (0)
The in vivo coating of tumor cells by potentially cytotoxic antitumor antibodies. (1976) (0)
Tumor-Endothelium Interactions – Novel Pathways (2005) (0)
Generation and Characterization of Novel Local and Metastatic Human Neuroblastoma Variants 1 , 2 (2008) (0)
Suppression of the immune response by alloantibodies. (1971) (0)
In vitro exposure of polyoma-virus-transformed cells to laminin augments their in vivo malignancy phenotype. (1993) (0)
Some Characteristics of Non-Immunoglobulin Components in Low pH Extracts of A Non-Lymphoid Tumor (1983) (0)
The Pyst2-L phosphatase is involved in cell-crowding. (2006) (0)
Cellular selection and regulation in the immune response: by G.M. Edelman (ed.) Raven Press, New York - North-Holland, Amsterdam, 1974 (332 pp., illus.) $19.75 (1975) (0)
753 Chemokines, chemokine receptors and selectin ligands expression by tumour cells: Involvement in extravasation and metastasis (2003) (0)
Proceedings: Degradation of antitumor antibodies by lysosomal enzymes: the blocking effect of the degradation products. (1975) (0)
Proceedings: Evidence for the coating of specific antigenic sites on polyoma-induced tumor cells during growth in a syngeneic host. (1975) (0)
Cancer microenvironment and genomics: evolution in process (2021) (0)
2' Deoxycoformycin and human hemopoietic cells in culture. (1984) (0)
F-105 Site-specific metastasis revisited (2016) (0)
Membrane antigens associated with infection, transformation, and tumorigenesis by polyoma virus (2004) (0)
Cytotoxic Action of Anti-urine Sera on Mouse Tumour Cells (1963) (0)
The Effect of Dimethylbenzanthracene on the NK Activity of Mice (1983) (0)
Immune functions and hematopoietic progenitor cell activity in plasmacytoma-bearing mice cured by melphalan. (1987) (0)
Delivery of packaged mail in the tumor microenvironment. (2019) (0)
Degradation of tumor antibodies by tumor cells in culture. Abstr. (1977) (0)
Monoclonal igm as a tumor-specific transplantation antigen. (1975) (0)
Tumor cell mediated degradation in vitro of antitumor antibodies. (1979) (0)
The blocking activity of antitumor alloantibodies treated with tumor- -derived lysosomal extracts. (1975) (0)
A history of exploring cancer in context (2018) (0)
30 Neuroblastoma and melanoma metastasis: regulation by the tumour microenvironment (2010) (0)
Precipitins and cytotoxins in antiurine sera. Abstr. (1963) (0)
Tumor-associated immunoglobulins: nature of the association. (1972) (0)

This paper list is powered by the following services:

Other Resources About Isaac Witz

en.wikipedia.org

What Schools Are Affiliated With Isaac Witz?

Isaac Witz is affiliated with the following schools:

Isaac Witz's Academic­Influence.com Rankings

Isaac Witz's Degrees

Why Is Isaac Witz Influential?

Isaac Witz's Published Works

Published Works

Other Resources About Isaac Witz

What Schools Are Affiliated With Isaac Witz?

Isaac Witz's AcademicInfluence.com Rankings